Gene Regulatory Effect of Pyruvate Kinase M2 is Involved in Renal Inflammation in Type 2 Diabetic Nephropathy

Abstract

Background and Aims The inflammation of glomerular endothelial cells induces and promotes the activation of macrophages and contributes to the development of diabetic nephropathy. Thus, this study aimed to investigate the gene regulatory effect and potential role of pyruvate kinase M2 (PKM2) in inflammatory response in diabetic nephropathy.

Methods The plasma PKM2 levels of patients with diabetes were evaluated. Eight-week-old mice were divided into three groups (WT, db/db mice, and db/db mice treated with TEPP-46) and raised for 12 weeks. Blood and kidney samples were collected at the end of the experiment. Endothelial cells were stimulated with high glucose with or without TEPP-46. The expression of intercellular adhesion molecule 1 (ICAM-1), interleukin 6 (IL-6), interleukin 1 beta (IL-1β), phospho-PKM2, PKM2, phospho-STAT3(signal transducer and activator of transcription), STAT3, nuclear factor kappa B (NF-kB), and phospho-NF-kB in vivo and in vitro were determined using Western blot. The activation of macrophages (CD68⁺CD86⁺) in the glomeruli was assessed via fluorescent double staining. Moreover, immune endothelial adhesion experiments were performed.

Results The plasma PKM2 levels of patients with type 2 diabetes increased. P-PKM2 was up-regulated in vivo and in vitro. TEPP-46 decreased inflammatory cell infiltration and ICAM-1 expression in vivo and in vitro and inhibited the differentiation of macrophages to M1 cells in db/db mice with diabetic nephropathy. PKM2 regulated the phosphorylation of STAT3 and NF-kB. Furthermore, high glucose levels induced the transition from tetramer to dimer and the nuclear translocation of PKM2.

Conclusion The gene regulatory effect of PKM2 is involved in renal inflammation in type 2 diabetic nephropathy by promoting the phosphorylation of STAT3 and NF-kB and the expression of intercellular adhesion molecule 1. Thus, the down-regulation of phosphorylated PKM2 may have protective effects against diabetic nephropathy by inhibiting renal inflammation.

Key words

PKM2 - gene regulatory effects - type 2 diabetic nephropathy - renal inflammation - ICAM-1

Publication History

Received: 19 April 2019
Received: 31 October 2019

Accepted: 25 November 2019

Article published online:
20 January 2020

• References

• 1 Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes 2014; 5: 393-398
• 2 Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867
• 3 Palsson-McDermott EM, Curtis AM, Goel G. et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction, and is a critical determinant of the Warburg Effect in LPS-activated macrophages. Cell Metab 2015; 21: 65-80
• 4 Wang F, Wang K, Xu W. et al. SIRT5 Desuccinylates and activates pyruvate kinase M2 to block macrophage IL-1β production and to Prevent DSS-Induced Colitis in Mice. Cell Rep 2017; 19: 2331-2344
• 5 Qi W, Keenan HA, Li Q. et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med 2017; 23: 753-762
• 6 Roigas J, Deger S, Schroeder J. et al. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 31: 358-362
• 7 Shang J, Wang L, Zhang Y. et al. Chemerin/ChemR23 axis promotes inflammation of glomerular endothelial cells in diabetic nephropathy. J Cell Mol Med 2019; 23: 3417-3428
• 8 Chen L, Zhang J, Zhang Y. et al. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm Res 2008; 57: 199-204
• 9 Lei CT, Su H, Ye C. et al. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure. J Cell Mol Med 2018; 22: 251-260
• 10 Sierra-Mondragon E, Molina-Jijon E, Namorado-Tonix C. et al. All-trans retinoic acid ameliorates inflammatory response mediated by TLR4/NF-κB during initiation of diabetic nephropathy. J Nutr Biochem 2018; 60: 47-60
• 11 Wung BS, Hsu MC, Wu CC. et al. Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: Effects on the inhibition of STAT3 phosphorylation. Life Sci 2005; 78: 389-397
• 12 Chang Y, Moradi H, Kalantar-Zadeh K. Emerging paradigms of treating diabetic nephropathy. Lancet Diabetes Endocrinol 2018; 6: 912-913
• 13 Shirai T, Nazarewicz RR, Wallis BB. et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med 2016; 213: 337-354
• 14 Kong Q, Li N, Cheng H. et al. HSPA12A is a novel player in nonalcoholic steatohepatitis via promoting nuclear PKM2-mediated M1 macrophage polarization. Diabetes 2019; 68: 361-376
• 15 Hu K, Yang Y, Lin L. et al. Caloric restriction mimetic 2-deoxyglucose alleviated inflammatory lung injury via suppressing nuclear pyruvate kinase M2-signal transducer and activator of transcription 3 pathway. Front Immunol 2018; 9: 426
• 16 Amdur RL, Feldman HI, Gupta J. et al. Inflammation and progression of CKD: The CRIC Study. Clin J Am Soc Nephrol 2016; 11: 1546-1556
• 17 Chow FY, Nikolic-Paterson DJ, Ozols E. et al. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005; 16: 1711-1722
• 18 Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep 2006; 6: 463-468
• 19 Alves-Filho JC, Pålsson-McDermott EM. Pyruvate kinase M2: A potential target for regulating inflammation. Front Immunol 2016; 7: 145
• 20 Lü S, Deng J, Liu H. et al. PKM2-dependent metabolic reprogramming in CD4⁺ T cells is crucial for hyperhomocysteinemia-accelerated atherosclerosis. J Mol Med 2018; 96: 585-600
• 21 Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001; 59: 415-424
• 22 Schmid H, Boucherot A, Yasuda Y. et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55: 2993-3003
• 23 Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm 2012; 2012: 146-154
• 24 Zitman-Gal T, Einbinder Y, Ohana M. et al. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells. J Diabetes 2019; 11: 656-664
• 25 Berthier CC, Zhang H, Schin M. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009; 58: 469-477
• 26 Lu T-C, Wang Z-H, Feng X. et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int 2009; 76: 63-71
• 27 Bruno RM, Reesink KD, Ghiadoni L. Advances in the non-invasive assessment of vascular dysfunction in metabolic syndrome and diabetes: Focus on endothelium, carotid mechanics and renal vessels. Nutr Metab Cardiovasc Dis 2017; 27: 121-128
• 28 Fu J, Lee K, Chuang PY. et al. Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol 2015; 308: F287-F297
• 29 Saito D, Maeshima Y, Nasu T. et al. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol 2011; 300: F873-F886
• 30 Zac-Varghese S, Winocour P. Managing diabetic kidney disease. Br Med Bull 2018; 125: 55-66
• 31 Almousa AA, Morris M, Fowler S. et al. Elevation of serum pyruvate kinase M2 (PKM2) in IBD and its relationship to IBD indices. Clin Biochem 2018; 53: 19-24
• 32 Scott SE, Bouhenni RA, Chomyk AM. et al. Anti-retinal antibodies in serum of laser-treated rabbits. Invest Ophthalmol Vis Sci 2012; 53: 1764-1772
• 33 Paulus YM, Kuo C-H, Morohoshi K. et al. Serum inflammatory markers after rupture retinal laser injury in mice. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 362-368
• 34 Gordin D, Shah H, Shinjo T. et al. Characterization of glycolytic enzymes and pyruvate kinase M2 in type 1 and 2 diabetic nephropathy. Diabetes Care. 2019; 42: 1263-1273
• 35 Lavoz C, Matus YS, Orejudo M. et al. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy. Kidney Int 2019; 95: 1418-1432
• 36 Bettelli E, Carrier Y, Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238
• 37 Kono M, Maeda K, Stocton-Gavanescu I et al. Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight. 2019; 4: pii: 127395
• 38 Lv L, Li D, Zhao D. et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 2011; 42: 719-730